Plain-English translation of NCT07342231 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This trial is testing a new scanning technique called Gallium-68 FAPi PET that may help doctors see pancreatic cancer more clearly than standard CT scans. The scan works by using a radioactive tracer that attaches to a specific protein found on cancer cells, making tumors and any spread more visible. Researchers want to find out if this new scan is better at detecting pancreatic cancer and identifying where it may have spread to other parts of the body.
Standard CT scans sometimes miss parts of pancreatic tumors and the tissue around them that helps cancer spread. This trial exists to see whether this new scanning method can detect cancer more accurately and help doctors plan better treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the new Gallium-68 FAPi PET scan in addition to your standard CT scan. The study compares the results of both scans to see if the new method detects your cancer better. The researchers are enrolling about 60 participants total, including both people newly diagnosed with pancreatic cancer and those whose cancer has returned after treatment.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
India
Enrollment target
~60 participants
Started
January 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sushil Yadav, MSc
Tata Memorial Hospital, Mumbai
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.